Key Points
• Immuron’s IMM-124E IND Program recommences
• Uniformed Services University to recommence planned Travelers’ Diarrhea clinical study
• COVID-19 - Consultancy Agreement with Infectious Disease Epidemiologist at Wayne
State University
Melbourne, Australia, October 12, 2020: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an
Australian biopharmaceutical company focused on developing and commercialising oral
immunotherapeuticsfor the prevention and treatment of gut mediated pathogens, today is pleased
to provide shareholders and the market with an update on the planned clinical programs in
Travelers’ Diarrhea (TD).
The Board of Immuron has approved company plans to recommence the CMC related activities
regarding its investigational drug IMM-124E required to support an investigational new drug (IND)
application to the FDA and the proposed phase III clinical study in TD.
The company has recently been advised by the Uniformed Services University (USU) that it has
recommenced the planned clinical trial program to evaluate the efficacy of non-antibiotic OTC
products in Travelers’ Diarrhea and will provide a purchase order for IMM-124E. USU’s Infectious
Diseases Clinical Research Program (IDCRP), the UK Ministry of Defense and the New York City Travel
Clinic are jointly conducting a randomized clinical trial to evaluate the efficacy of these nutraceutical
products for TD and inform strategies for Force Health Protection. The P4TD study is a randomized,
double-blind, placebo controlled multicenter clinical trial designed to evaluate the effectiveness of
3 commercially available nutraceuticals: A prebiotic (Bimuno®), a probiotic (Florastor®) and IMM124E (Travelan®) passive immunoprophylaxis verses a placebo, for prophylaxis during deployment
or travel to a high-TD risk region. All study participants (1336 in total) will be randomized to one of
the three active products or placebo (334 per arm).
The company is also pleased to announce that it has executed a consultancy agreement with
Professor Teena Chopra, Professor of Medicine Wayne State University School of Medicine, Detroit
Michigan. Professor Chopra is an Infectious Disease Epidemiologist with a specific interest in
Clostridiodes difficle (C.difficle) infections. Professor Chopra and her team recently published their
research findings on patients at a hospital associated with the Detroit Medical Center presenting
with both SARS-CoV-2 and C.difficle1. Both infections can manifest as digestive symptoms and merit
screening when assessing patients with diarrhea. The hospitals associated with the Detroit Medical
Centre treated over 600 patients presenting with COVID-19 during the peak of the pandemic.
Professor Chopra and her team noted most predominantly included pulmonary symptoms but a
small subset of less than 10% of the cases also included gastrointestinal events. Professor Chopra is
building a registry of the patients presenting with gastrointestinal events to better understand this
cohort and the unique medical challengesthey present and will be an invaluable resource to access.
“C. difficile infection (CDI) is a challenging disease, with a recurrence rate of 15%–20% and a
mortality rate of 5%. When CDI is present as a co-infection with COVID-19, CDI therapy can be
difficult to monitor if diarrhea persists because of COVID-19. Our most recent research findings
highlight the importance of judicious use of antibiotics for potential secondary bacterial infection in
patients with COVID-19. Antibiotics are known to have unintended consequences, such as C. difficile
infection. We recently identified 9 patients in our study who were elderly, an age group at higher
risk for complications from overuse of antibiotics, such as adverse events, antibiotic resistance, and
concomitant infections like CDI. Immuron’s technology platform is intriguing because it potentially
offers a non-antibiotic solution to this debilitating disease” said Professor Chopra.
- Forums
- ASX - By Stock
- IMC
- Ann: Immuron Travelers Diarrhea Market Update
Ann: Immuron Travelers Diarrhea Market Update, page-3
-
- There are more pages in this discussion • 110 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMC (ASX) to my watchlist
|
|||||
Last
9.5¢ |
Change
0.002(2.15%) |
Mkt cap ! $21.65M |
Open | High | Low | Value | Volume |
9.8¢ | 10.0¢ | 9.5¢ | $16.76K | 170.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 50946 | 9.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.0¢ | 160371 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 175838 | 0.091 |
1 | 500000 | 0.090 |
2 | 111235 | 0.089 |
2 | 61363 | 0.088 |
1 | 32500 | 0.085 |
Price($) | Vol. | No. |
---|---|---|
0.100 | 160371 | 2 |
0.105 | 295769 | 3 |
0.110 | 121204 | 4 |
0.115 | 50000 | 1 |
0.120 | 138000 | 3 |
Last trade - 15.34pm 06/09/2024 (20 minute delay) ? |
Featured News
IMC (ASX) Chart |